Wikisage, the free encyclopedia of the second generation, is digital heritage
Flibanserin: Difference between revisions
Jump to navigation
Jump to search
(→Links: 2) |
(→Links) |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
flibaserin is a new FDA aproved drug, it was formerly developed in Europe by Boeringer Ingelheim latter in US by Sprout Pharmaceutical due it refusal by Health Authority in 2013<ref>http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM215437.pdf</ref>Flibanserin is a post-synaptic 5-hydroxytryptamine (5-HT) 1A receptor agonist and 5-HT 2A antagonist that has been evaluated for indications of major depressive disorder (MDD) and for the | |||
treatment of [[Hypoactive sexual desire disorder|HSDD]] in premenopausal women.<ref>http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM449088.pdf</ref> | |||
treatment of HSDD in premenopausal women.<ref>http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM449088.pdf</ref> | |||
<gallery>File:flibanserin-structural.svg.png</gallery> | <gallery>File:flibanserin-structural.svg.png</gallery> | ||
| Line 7: | Line 6: | ||
==Links== | ==Links== | ||
http://jama.jamanetwork.com/article.aspx?articleid=2389384 Evaluation of Flibanserin Science and Advocacy at the FDA | [http://jama.jamanetwork.com/article.aspx?articleid=2389384 Evaluation of Flibanserin Science and Advocacy at the FDA] | ||
http://informahealthcare.com/doi/pdf/10.1517/14656566.2015.1064393 Why are there no FDA-approved treatments for female sexual dysfunction? | [http://informahealthcare.com/doi/pdf/10.1517/14656566.2015.1064393 Why are there no FDA-approved treatments for female sexual dysfunction?] | ||
{{refs}} | |||
Latest revision as of 01:23, 8 July 2019
flibaserin is a new FDA aproved drug, it was formerly developed in Europe by Boeringer Ingelheim latter in US by Sprout Pharmaceutical due it refusal by Health Authority in 2013[1]Flibanserin is a post-synaptic 5-hydroxytryptamine (5-HT) 1A receptor agonist and 5-HT 2A antagonist that has been evaluated for indications of major depressive disorder (MDD) and for the treatment of HSDD in premenopausal women.[2]
Links
Evaluation of Flibanserin Science and Advocacy at the FDA
Why are there no FDA-approved treatments for female sexual dysfunction?
| References: |